# Chengdu IXING Biotechnology Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/chengdu-ixing-biotechnology-co

- Industry: Medical Devices & Equipment
- Headquarters: Chengdu, China
- Website: www.ixingbio.com
- Total disclosed funding: $2.8M
- Latest round: Series B (May 1, 2020)
- Investors on record: 3

## About

Based in Chengdu, China, and established in 2013, Chengdu IXING Biotechnology Co., Ltd. is an IVD company focusing on precise POCT technology platforms and products, with two R&D centers in Chengdu and Shanghai. In April 2021, seven products has obtained CE certificates.  In January 2019, IXING obtained the production license.

The company's products can be categorized into Point-of-care Testing (POCT) equipment and reagents, which can be applied in laboratories, outpatient clinics, emergency clinics, medical examination centers, health centers, etc. The reagents include cardiovascular and cerebrovascular disease rapid diagnosis series, infection and inflammation series, kidney injury series, maternal health series, and gastric function series.  It also provides myocardial complex quality control products and inflammation complex quality control products.

## Funding rounds

- Series B, May 1, 2020, $2.8M — Yushan Partners
- Series A, Jun 8, 2018 — Sichuan Juxin-Development Investment Fund Management
- Series A, Feb 1, 2017 — YuanBio Venture

## Investors

- YuanBio Venture (https://capitalatlas.ai/funds/yuanbio-venture) — Series A
- Sichuan Juxin-Development Investment Fund Management (https://capitalatlas.ai/funds/sichuan-juxin-development-investment-fund-management) — Series A
- Yushan Partners (https://capitalatlas.ai/funds/yushan-partners) — Series B